Our analysis of earlier earnings waves highlighted a clear trend: companies actively shedding non-core assets to regain focus. The mid-February earnings window (Feb 14–22) demonstrated the tangible financial outcomes of that strategy. We are seeing a distinct shift in market expectations, characterized by significant M&A activity, a strict demand for GAAP profitability among mid-caps, and a low tolerance for administrative missteps. For the C-Suite, the mandate for 2026 is st

The latest wave of MedTech earnings (Zimmer Biomet, Baxter, Teleflex, Dexcom, West Pharma) delivered a brutal but clarifying message to the industry: Complexity is now a liability. For the last decade, the winning strategy was "bigger is safer." Accumulate assets, bundle contracts, and ride the scale. In 2026, that logic has inverted. The market is aggressively punishing broad portfolios and rewarding ruthless specialization. Here are the three signals from this week that eve

Selected earnings coverage of Medical Device companies from 2-2-2025 through 2-7-2026 indicate that execution is still the most critical part of successful company culture. Boston Scientific, GE Healthcare, Siemens Healthineers, and Steris all show this focus will be around in 2026 and beyond.

Investors stopped rewarding vague promises this week. They want hard numbers and actual resilience. We just saw another wave of earnings (Stryker, Thermo Fisher, Roche, Elevance, DaVita), and the message to the C-Suite is clear: Stop hiding behind "macro uncertainty" and tell us your plan. Here is the reality check from the last few days: 1. You Have to Name the Number Stryker didn't flinch. They admitted tariffs will cost them $400M  next year. But they also laid out exactl

The "wait and see" era is over. This week’s earnings calls (Jan 27–28) confirmed a fundamental shift: The market is no longer rewarding medtech companies just for growing. It is rewarding them for resilience. Check back throughout the coming weeks as I cover additional companies and the running comparison chart grows. Reach out to us directly if you have a company you'd like included: hello@allons-y.co If you’re a CEO or CFO in this space, your 2026 playbook just changed. H

As an executive or independent consultant, you're constantly making high-stakes decisions. The value of a strong advisory board is...

In every executive team, there comes a moment when the CEO cringes: an interview goes sideways, a deck to a key partner misrepresents the...

As a former multi-sport athlete, I cherish the lessons learned from my teammates, coaches, and competitors: perseverance, teamwork,...